Cargando…
Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive myeloid disorder that is associated with a generally poor prognosis. Effective treatment options have been limited for older patients with AML who are not able to undergo intensive remission induction chemotherapy due to advanced age or comorbidities. Ne...
Autores principales: | Thompson, Daniel L., Moore, Donald C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848813/ https://www.ncbi.nlm.nih.gov/pubmed/33532119 http://dx.doi.org/10.6004/jadpro.2020.11.2.8 |
Ejemplares similares
-
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019) -
Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020) -
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021) -
Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022) -
A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019)